Skip to main content

Mild Cognitive Impairment

28
Pipeline Programs
30
Companies
50
Clinical Trials
7 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
9
1
14
0
2
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
250%
Small Molecule
250%
+ 69 programs with unclassified modality

Competitive Landscape

49 companies ranked by most advanced pipeline stage

Hanmi Pharmaceutical
1
Acetyl-L-carnitine hydrochloride 500mgPhase 41 trial
Active Trials
NCT04346862Unknown636Est. Jun 2020
Chong Kun Dang Pharmaceutical
1
Choline AlfosceratePhase 41 trial
Active Trials
NCT05041790Unknown418Est. Nov 2024
Medpace
MedpaceCINCINNATI, OH
1 program
1
FlutemetamolPhase 31 trial
Active Trials
NCT01028053Completed365Est. Jan 2014
Medica Corp
Medica CorpMA - Bedford
1 program
1
MMH-MAPPhase 31 trial
Active Trials
NCT03815292Completed276Est. Jan 2020
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
7 programs
2
1
Grape PowderPhase 21 trial
Grape PowderPhase 11 trial
bosutinibPhase 1Small Molecule1 trial
Memory TrainingN/A1 trial
Tai ChiN/A1 trial
+2 more programs
Active Trials
NCT03503669Completed100Est. Feb 2021
NCT05217849Completed77Est. Dec 2025
NCT05235113Active Not Recruiting84Est. Jun 2026
+4 more trials
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
4 programs
2
CannabidiolPhase 21 trial
PioglitazonePhase 21 trial
Advance Care Planning Group VisitsN/A1 trial
Cross-Cultural Use of Performance-Based Functional Assessment in Alzheimer's DiseaseN/A1 trial
Active Trials
NCT03711396Completed26Est. Jan 2021
NCT03081546Completed41Est. Sep 2018
NCT05822362Recruiting236Est. Apr 2029
+1 more trials
Sandoz
SandozAustria - Kundl
2 programs
1
CanakinumabPhase 2Monoclonal Antibody1 trial
Clinical Pathway for Alzheimer's Disease in China (CPAD)N/A1 trial
Active Trials
NCT01779310Completed1,024Est. Apr 2013
NCT04795466Terminated34Est. Mar 2024
ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
1
1
RosiglitazonePhase 2
GSK239512Phase 1
Araclon Biotech
1
ABvac40Phase 21 trial
Active Trials
NCT03461276Completed134Est. Mar 2023
AgeneBio
1 program
1
AGB101Phase 21 trial
Active Trials
NCT05986721Withdrawn0Est. Dec 2028
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD5213Phase 21 trial
Active Trials
NCT01548287Completed164Est. Jan 2013
CuraSen Therapeutics
CuraSen TherapeuticsCA - San Carlos
1 program
1
CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107Phase 21 trial
Active Trials
NCT05104463Completed64Est. Feb 2024
RespireRx Pharmaceuticals
1
CX516Phase 21 trial
Active Trials
NCT00040443Completed175Est. Jun 2004
Biomed
1 program
1
N-831Phase 21 trial
Active Trials
NCT03538522Completed126Est. Oct 2019
Servier
ServierFrance - Suresnes
1 program
1
S18986Phase 21 trial
Active Trials
NCT00202540Terminated38Est. Mar 2006
Supernus Pharmaceuticals
1 program
1
SAGE-718Phase 21 trial
Active Trials
NCT05619692Completed174Est. Jul 2024
Navidea Biopharmaceuticals
1
[18F]NAV4694Phase 21 trial
Active Trials
NCT01812213Terminated76Est. Nov 2017
Oregon Therapeutics
2
1
Staying Sharp interventionPhase 1/21 trial
Active social engagement groupPhase 11 trial
Centella asiatica productPhase 11 trial
dual-task tai ji quanN/A1 trial
tai ji quanN/A1 trial
Active Trials
NCT05725668Recruiting336Est. Jan 2028
NCT05318703Completed69Est. Oct 2022
NCT01571427Completed83Est. Sep 2013
+2 more trials
Insightec
InsightecFL - Miami
1 program
1
AducanumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT05469009Active Not Recruiting15Est. Jul 2029
Eyenuk
1 program
1
Retinal fundus photographyPhase 11 trial
Active Trials
NCT04567745Completed80Est. Sep 2021
Cognoptix
1 program
1
Sapphire IIPhase 11 trial
Active Trials
NCT02928211Unknown105Est. Jan 2019
Pfizer
PfizerNEW YORK, NY
1 program
1
bosutinibPhase 1Small Molecule
Innovation Pharmaceuticals
3 programs
ABI Wellness ProgramN/A1 trial
Brain Blossom - Gamified Differential Outcome TrainingN/A1 trial
Shanghai Mild Cognitive Impairment Cohort StudyN/A1 trial
Active Trials
NCT04539132Unknown40Est. Oct 2021
NCT06399978Not Yet Recruiting40Est. Jan 2025
NCT01552265Completed400Est. Jul 2017
Human BioSciences
APOE genotype and Alzheimer's disease risk disclosureN/A1 trial
One Resistance Training SetN/A1 trial
Transcutaneous vagal nerve stimulationN/A1 trial
Active Trials
NCT01434667Completed146Est. Jul 2014
NCT06185010Recruiting80Est. Dec 2024
NCT03359902Completed59Est. May 2022
UNION therapeutics
Cybercycle-GameN/A1 trial
Lumbar punctureN/A1 trial
engAGE systemN/A1 trial
Active Trials
NCT02237560Completed111Est. Jul 2017
NCT01425957Completed229Est. Oct 2015
NCT06302686Unknown78Est. Jun 2024
Eisai
EisaiChina - Liaoning
2 programs
group cognitive interventionN/A1 trial
AriceptPHASE_41 trial
Active Trials
NCT01358955Completed293Est. Jan 2013
NCT00934375Completed145Est. Sep 2007
GSK
GSKLONDON, United Kingdom
2 programs
GSK239512PHASE_11 trial
RosiglitazonePHASE_21 trial
Active Trials
NCT00474513Completed5Est. Mar 2008
NCT00242593Unknown120Est. Dec 2011
GE HealthCare
2 programs
[18F] FlutemetamolPHASE_21 trial
FlutemetamolPHASE_3
Active Trials
NCT02813070Completed70Est. May 2013
Genome & Company
APOE genotype and Alzheimer's disease risk disclosureN/A
Biocorp
1 program
Alzheimer's and Blood Glucose LevelsN/A1 trial
Active Trials
NCT04614376Unknown100Est. Mar 2022

+19 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Chong Kun Dang PharmaceuticalCholine Alfoscerate
Hanmi PharmaceuticalAcetyl-L-carnitine hydrochloride 500mg
EisaiAricept
Medica CorpMMH-MAP
MedpaceFlutemetamol
AgeneBioAGB101
Colorado TherapeuticsCannabidiol
Supernus PharmaceuticalsSAGE-718
CuraSen TherapeuticsCST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107
SandozCanakinumab
Function TherapeuticsThe Computerized Functional Skills Assessment and Training Program
Precision BioSciencesAtorvastatin Oral Tablet
FUJIFILM PharmaT-817MA
BiomedN-831
Araclon BiotechABvac40

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 6,425 patients across 50 trials

A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment

Start: Sep 2021Est. completion: Nov 2024418 patients
Phase 4Unknown
NCT04346862Hanmi PharmaceuticalAcetyl-L-carnitine hydrochloride 500mg

Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease

Start: Jan 2016Est. completion: Jun 2020636 patients
Phase 4Unknown

A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment

Start: Feb 2006Est. completion: Sep 2007145 patients
Phase 4Completed

Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke

Start: Oct 2018Est. completion: Jan 2020276 patients
Phase 3Completed
NCT01028053MedpaceFlutemetamol

Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease

Start: Dec 2009Est. completion: Jan 2014365 patients
Phase 3Completed

Clinical Trial of AGB101 for Mild Cognitive Impairment

Start: Dec 2024Est. completion: Dec 20280
Phase 2Withdrawn

CBD for Individuals at Risk for Alzheimer's Disease

Start: Jan 2024Est. completion: Apr 2029236 patients
Phase 2Recruiting

A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

Start: Nov 2022Est. completion: Jul 2024174 patients
Phase 2Completed
NCT05104463CuraSen TherapeuticsCST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107

A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease

Start: Apr 2022Est. completion: Feb 202464 patients
Phase 2Completed

Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease

Start: Oct 2021Est. completion: Mar 202434 patients
Phase 2Terminated
NCT04679441Function TherapeuticsThe Computerized Functional Skills Assessment and Training Program

A Novel Computer-Based Functional Skills Assessment and Training Program

Start: Aug 2021Est. completion: May 2023180 patients
Phase 2Active Not Recruiting
NCT04765137Precision BioSciencesAtorvastatin Oral Tablet

Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)

Start: May 2021Est. completion: Dec 202620 patients
Phase 2Recruiting

Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

Start: Dec 2019Est. completion: Mar 2023221 patients
Phase 2Completed

A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831

Start: Sep 2018Est. completion: Oct 2019126 patients
Phase 2Completed

Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD

Start: Dec 2017Est. completion: Mar 2023134 patients
Phase 2Completed

Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance Over 1 Year

Start: Nov 2017Est. completion: Oct 202232 patients
Phase 2Completed

Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI

Start: Mar 2013Est. completion: Nov 201776 patients
Phase 2Terminated

Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

Start: Nov 201252 patients
Phase 2Completed
NCT02813070GE HealthCare[18F] Flutemetamol

Comparison of PET Amyloid Imaging in Japanese and Western Subjects

Start: Oct 2012Est. completion: May 201370 patients
Phase 2Completed

A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment

Start: Apr 2012Est. completion: Jan 2013164 patients
Phase 2Completed

Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI)

Start: Nov 2008Est. completion: Dec 201378 patients
Phase 2Completed
NCT00242593GSKRosiglitazone

Rosiglitazone Effects on Cognition for Adults in Later Life

Start: Jun 2006Est. completion: Dec 2011120 patients
Phase 2Unknown

Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients

Start: Jun 2005Est. completion: Mar 200638 patients
Phase 2Terminated

Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.

Start: Apr 2002Est. completion: Jun 2004175 patients
Phase 2Completed
NCT05260515Oregon TherapeuticsStaying Sharp intervention

Protecting Alzheimer Caregivers Using Technology Through Staying Sharp

Start: Apr 2023Est. completion: Aug 2024138 patients
Phase 1/2Unknown
NCT05591027Oregon TherapeuticsCentella asiatica product

Safety and Target Engagement of Centella Asiatica in Cognitive Impairment

Start: Dec 2022Est. completion: Mar 202648 patients
Phase 1Recruiting

Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy

Start: Jul 2022Est. completion: Jul 202915 patients
Phase 1Active Not Recruiting
NCT01464515BrainsWayH-Coil Deep TMS

Efficiency of Deep Transcranial Magnetic Stimulation on Patients With Mild Cognitive Impairment

Start: Jan 2021Est. completion: Jan 202130 patients
Phase 1Unknown
NCT04567745EyenukRetinal fundus photography

Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers

Start: Sep 2020Est. completion: Sep 202180 patients
Phase 1Completed

A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.

Start: May 2019Est. completion: May 20220
Phase 1Withdrawn

Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative Dementias

Start: Sep 2016Est. completion: Dec 2025150 patients
Phase 1Unknown

Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations

Start: Jul 2016Est. completion: Jan 2019105 patients
Phase 1Unknown

Impact of Grape Consumption on Brain Metabolism and Cognitive Function

Start: Apr 2012Est. completion: Nov 201412 patients
Phase 1Completed
NCT01571427Oregon TherapeuticsActive social engagement group

Conversations as a Means to Delay the Onset of Alzheimer's Disease

Start: Feb 2012Est. completion: Sep 201383 patients
Phase 1Completed

An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.

Start: Mar 2007Est. completion: Mar 20085 patients
Phase 1Completed

Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers

Start: Mar 2025Est. completion: Mar 2026500 patients
N/ARecruiting
NCT06762522Providence TherapeuticsNonlinear dynamical neurofeedback

Exploring Feasibility, Acceptability and Impact of Using Neurofeedback with Persons with Mild Cognitive Impairment

Start: Jan 2025Est. completion: Jan 202620 patients
N/ANot Yet Recruiting

Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)

Start: May 2024Est. completion: Dec 2027380 patients
N/ARecruiting
NCT06399978Innovation PharmaceuticalsBrain Blossom - Gamified Differential Outcome Training

The Feasibility and Effect of Digital Cognitive Training in Mild Cognitive Impairment

Start: May 2024Est. completion: Jan 202540 patients
N/ANot Yet Recruiting
NCT06185010Human BioSciencesOne Resistance Training Set

Resistance Training to Individuals for Cognitive Impairment With Dementia

Start: Dec 2023Est. completion: Dec 202480 patients
N/ARecruiting
NCT05235113Angeles TherapeuticsTele-Exergame Platform

Remote Game-based Exercise Program for Cognitive and Motor Function Improvement

Start: Nov 2023Est. completion: Jun 202684 patients
N/AActive Not Recruiting

engAGE: Managing cognitivE decliNe throuGh Theatre Therapy, Artificial Intelligence and Social Robots drivEn Interventions

Start: Oct 2023Est. completion: Jun 202478 patients
N/AUnknown
NCT05725668Oregon Therapeuticsdual-task tai ji quan

A Study of Dual-task Exercise Training to Prevent Falls Among Older Adults With Mild Cognitive Impairment

Start: Jul 2023Est. completion: Jan 2028336 patients
N/ARecruiting

Effects of Walkasins on Gait Speed of Individuals With Mild Cognitive Impairments

Start: Feb 2023Est. completion: Mar 202312 patients
N/ACompleted

Multi-domain Online Therapeutic Investigation Of Neurocognition (MOTION)

Start: Feb 2022Est. completion: Dec 202577 patients
N/ACompleted
NCT04954183SPARK BiopharmaDevelopment of an EEG Diagnostic for Alzheimer's Disease

Development of an EEG Diagnostic for Alzheimer's Disease

Start: Oct 2021Est. completion: Jul 202529 patients
N/ACompleted

Virtual Exercise For Older Adults With Mild Cognitive Impairment

Start: Jan 2021Est. completion: Oct 202269 patients
N/ACompleted
NCT04614376BiocorpAlzheimer's and Blood Glucose Levels

Alzheimer's and Blood Glucose Levels

Start: Nov 2020Est. completion: Mar 2022100 patients
N/AUnknown
NCT04683835NeurosteerNeurosteer Aurora system

Evaluation of Cognitive State in Senior Subjects Using Neurosteer EEG System

Start: Oct 2020Est. completion: Oct 202180 patients
N/ACompleted

Maintaining Independence and Quality of Life in Aging Adults Through Targeted Cognitive Training

Start: Sep 2020Est. completion: Oct 202140 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
7 actively recruiting trials targeting 6,425 patients
30 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.